z-logo
open-access-imgOpen Access
Practical Applications for Single Pill Combinations in the Cardiovascular Continuum
Author(s) -
Ferdinando Iellamo,
Karl Werdan,
Krzysztof Narkiewicz,
Giuseppe Rosano,
Maurizio Volterrani
Publication year - 2017
Publication title -
cardiac failure review
Language(s) - English
Resource type - Journals
eISSN - 2057-7559
pISSN - 2057-7540
DOI - 10.15420/cfr.2017:5:1
Subject(s) - polypill , medicine , tolerability , pill , ivabradine , combination therapy , intensive care medicine , adverse effect , disease , drug , angina , fixed dose combination , coronary heart disease , heart failure , pharmacology , blood pressure , heart rate , myocardial infarction
Despite the availability of new drugs and devices, the treatment of cardiovascular disease remains suboptimal. Single-pill combination therapy offers a number of potential advantages. It can combine different classes of drugs to increase efficacy while mitigating the risks of treatment-related adverse events, reduce pill burden, lower medical cost, and improve patient adherence. Furthermore, in hypertension, single pill combinations include lower doses of each drug than would be necessary to achieve goals with monotherapy, which may explain their better tolerability compared with higher dose monotherapy. Combination therapy is now established in the treatment of hypertension. In ischaemic heart disease, the concept of a preventative polypill has been studied, but its benefits have not been established conclusively. However, the combination of ivabradine and beta-blockers has proven efficacy in patients with stable angina pectoris. This combination has also demonstrated benefits in patients with chronic heart failure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom